PURPOSE: Tocopherols are lipophilic antioxidants present in vegetable oils. Although the antioxidant and anticancer activities of alpha-tocopherol (vitamin E) have been studied for decades, recent intervention studies with alpha-tocopherol have been negative for protection from cancer in humans. The tocopherols consist of four isoforms, which are the alpha, beta, gamma, and delta variants, and recent attention is being given to other isoforms. In the present study, we investigated the inhibitory effect of a tocopherol mixture rich in gamma- and delta-tocopherols against mammary tumorigenesis. EXPERIMENTAL DESIGN: Female Sprague Dawley rats were treated with N-methyl-N-nitrosourea (NMU), and then fed diets containing 0.1%, 0.3%, or 0.5% mixed tocopherols rich in gamma- and delta-tocopherols for 9 weeks. Tumor burden and multiplicity were determined, and the levels of markers of inflammation, proliferation, and apoptosis were evaluated in the serum and in mammary tumors. The regulation of nuclear receptor signaling by tocopherols was studied in mammary tumors and in breast cancer cells. RESULTS: Dietary administration of 0.1%, 0.3%, or 0.5% mixed tocopherols suppressed mammary tumor growth by 38%, 50%, or 80%, respectively. Tumor multiplicity was also significantly reduced in all three mixed tocopherol groups. Mixed tocopherols increased the expression of p21, p27, caspase-3, and peroxisome proliferator activated receptor-gamma, and inhibited AKT and estrogen signaling in mammary tumors. Our mechanistic study found that gamma- and delta-tocopherols, but not alpha-tocopherol, activated peroxisome proliferator activated receptor-gamma and antagonized estrogen action in breast cancer. CONCLUSION: The results suggest that gamma- and delta-tocopherols may be effective agents for the prevention of breast cancer.
PURPOSE:Tocopherols are lipophilic antioxidants present in vegetable oils. Although the antioxidant and anticancer activities of alpha-tocopherol (vitamin E) have been studied for decades, recent intervention studies with alpha-tocopherol have been negative for protection from cancer in humans. The tocopherols consist of four isoforms, which are the alpha, beta, gamma, and delta variants, and recent attention is being given to other isoforms. In the present study, we investigated the inhibitory effect of a tocopherol mixture rich in gamma- and delta-tocopherols against mammary tumorigenesis. EXPERIMENTAL DESIGN: Female Sprague Dawley rats were treated with N-methyl-N-nitrosourea (NMU), and then fed diets containing 0.1%, 0.3%, or 0.5% mixed tocopherols rich in gamma- and delta-tocopherols for 9 weeks. Tumor burden and multiplicity were determined, and the levels of markers of inflammation, proliferation, and apoptosis were evaluated in the serum and in mammary tumors. The regulation of nuclear receptor signaling by tocopherols was studied in mammary tumors and in breast cancer cells. RESULTS: Dietary administration of 0.1%, 0.3%, or 0.5% mixed tocopherols suppressed mammary tumor growth by 38%, 50%, or 80%, respectively. Tumor multiplicity was also significantly reduced in all three mixed tocopherol groups. Mixed tocopherols increased the expression of p21, p27, caspase-3, and peroxisome proliferator activated receptor-gamma, and inhibited AKT and estrogen signaling in mammary tumors. Our mechanistic study found that gamma- and delta-tocopherols, but not alpha-tocopherol, activated peroxisome proliferator activated receptor-gamma and antagonized estrogen action in breast cancer. CONCLUSION: The results suggest that gamma- and delta-tocopherols may be effective agents for the prevention of breast cancer.
Authors: Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark Journal: JAMA Date: 2006-06-05 Impact factor: 56.272
Authors: Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark Journal: J Natl Cancer Inst Date: 2005-11-16 Impact factor: 13.506
Authors: Regina Brigelius-Flohé; Frank J Kelly; Jukka T Salonen; Jiri Neuzil; Jean-Marc Zingg; Angelo Azzi Journal: Am J Clin Nutr Date: 2002-10 Impact factor: 7.045
Authors: Nanjoo Suh; Shiby Paul; Hong Jin Lee; Yan Ji; Mao-Jung Lee; Chung S Yang; Bandaru S Reddy; Harold L Newmark Journal: Nutr Cancer Date: 2007 Impact factor: 2.900
Authors: Jihyeung Ju; Xingpei Hao; Mao-Jung Lee; Joshua D Lambert; Gang Lu; Hang Xiao; Harold L Newmark; Chung S Yang Journal: Cancer Prev Res (Phila) Date: 2009-01-20
Authors: Min Ji Bak; Philip Furmanski; Naing Lin Shan; Hong Jin Lee; Cheng Bao; Yong Lin; Weichung Joe Shih; Chung S Yang; Nanjoo Suh Journal: Carcinogenesis Date: 2018-07-30 Impact factor: 4.944
Authors: Shiby Paul; Cassia S Mizuno; Hong Jin Lee; Xi Zheng; Sarah Chajkowisk; John M Rimoldi; Allan Conney; Nanjoo Suh; Agnes M Rimando Journal: Eur J Med Chem Date: 2010-05-15 Impact factor: 6.514
Authors: Fei Guan; Guangxun Li; Anna B Liu; Mao-Jung Lee; Zhihong Yang; Yu-Kuo Chen; Yong Lin; Weichung Shih; Chung S Yang Journal: Cancer Prev Res (Phila) Date: 2012-02-24
Authors: Amanda K Smolarek; Jae Young So; Paul E Thomas; Hong Jin Lee; Shiby Paul; Anne Dombrowski; Chung-Xiou Wang; Constance Lay-Lay Saw; Tin Oo Khor; Ah-Ng Tony Kong; Kenneth Reuhl; Mao-Jung Lee; Chung S Yang; Nanjoo Suh Journal: Mol Carcinog Date: 2012-03-02 Impact factor: 4.784
Authors: Soumyasri Das Gupta; Jae Young So; Brian Wall; Joseph Wahler; Amanda K Smolarek; Sudathip Sae-Tan; Kelvin Y Soewono; Haixiang Yu; Mao-Jung Lee; Paul E Thomas; Chung S Yang; Nanjoo Suh Journal: Mol Carcinog Date: 2014-04-30 Impact factor: 4.784